Quote:

---

I agree. I'm sure Dr J is aware of this and also has a good idea of what the regulatory gatekeepers will approve and what they won't.

---

Most likely a discussion of adding PD-L1 inhibitors has taken place, thus the delay of the protocol approval.

Quote:

---

I also think we'll get the data we need in the CRC trial to prove PD-L1 Escalation and this will inform the protocol of the next trial to have both PD-L1 Escalation and checkpoint inhibitor.

---

For mCRC the best combination out their right now is TAS-102 and bevacizumab. We are using TAS-102 and bevacizumab in our trial. TAS-102 damages the tumor cells DNA and tries to kill those tumor cells. Bevacizumab is a VEGF inhibitor which leronlimab also does. What leronlimab brings to the table is stopping the tumor cell DNA repair after TAS-102 damages it allowing a complete kill. It reduces circulating tumor cells lessening metastatic burden and metastasis is often the primary reason for death. Leronlimab also increases killer macrophages leading to additional tumor cell death. The results will be hampered by not having a PD-L1 inhibitor, but the additional effects of leronlimab will surpass the two drug combo.